An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A batch of health stories is making the rounds, and the biggest thread ties together semaglutide (the drug behind brand names like Ozempic and Wegovy), research on eating disorders, and separate reports about vaping. In short: researchers and health reporters are raising questions about how widespread use of semaglutide might affect people with or at risk for eating disorders, while other updates about vaping highlight ongoing concerns. These are early signals, not final answers. Semaglutide is a medicine that copies a natural hormone your gut makes after you eat. That hormone tells your brain you’re full and also slows how quickly your stomach empties. Drugs using semaglutide are sold as Ozempic and Wegovy for diabetes and weight management. They make people feel less hungry and often lead to weight loss. Lots of people have heard the names because prescriptions have jumped and the drugs show big effects on appetite and body weight. The research mentioned here looks at links between taking semaglutide and changes in eating behaviors, and at how that intersects with eating disorders. Some studies and case reports note people on semaglutide experiencing loss of appetite, changes in how much or how often they eat, and in a few cases worsening of restrictive eating or other disordered eating patterns. A lot of the evidence so far comes from medical records, small studies, or individual cases — not large, long-term trials designed specifically to test how semaglutide affects people with eating disorders. That means the findings are worth paying attention to, but they don't prove that semaglutide causes eating disorders. They do show it can alter appetite and eating habits in ways that could be risky for some people. Why this matters for regular people: semaglutide is being used by many more patients now, including people seeking weight loss who don’t have diabetes. If you have a personal or family history of anorexia, bulimia, binge eating, or obsessive dieting, medication that changes appetite and weight could interact with those tendencies. For doctors and patients, the practical takeaway is to screen for past or current eating-disorder symptoms before starting treatment, to monitor mental health and eating patterns while on the drug, and to have a plan for stopping or adjusting therapy if problematic behaviors appear. There are important caveats. These drugs are approved for certain uses, and doctors prescribe them based on individual risk and benefit. Side effects commonly include nausea, stomach upset, and constipation; more serious but rare risks exist and long-term effects are still being studied. Because most of the reports linking semaglutide to eating-disorder issues are preliminary, we don’t have solid numbers on how often this happens or who is most at risk. If you’re considering semaglutide and have a history of disordered eating, talk openly with your clinician; don’t stop or start medications without medical advice. Bottom line: semaglutide changes appetite and can be very effective for weight and blood-sugar control, but people with a history of eating disorders should be carefully assessed and monitored because early reports suggest it could complicate disordered eating in some cases.
Source: WTOL